vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and KKR Real Estate Finance Trust Inc. (KREF). Click either name above to swap in a different company.
KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $15.0M, roughly 1.7× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -101.7%, a 103.5% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -26.6%). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -18.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
CSBR vs KREF — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $25.8M |
| Net Profit | $268.0K | $-26.2M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | -105.1% |
| Net Margin | 1.8% | -101.7% |
| Revenue YoY | 11.5% | -26.6% |
| Net Profit YoY | -63.2% | -229.6% |
| EPS (diluted) | $0.02 | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $25.8M | ||
| Q3 25 | $14.0M | $25.3M | ||
| Q2 25 | $12.4M | $30.2M | ||
| Q1 25 | $17.0M | $31.3M | ||
| Q4 24 | $13.5M | $35.1M | ||
| Q3 24 | $14.1M | $37.0M | ||
| Q2 24 | $14.0M | $40.4M | ||
| Q1 24 | $12.0M | $39.1M |
| Q4 25 | $268.0K | $-26.2M | ||
| Q3 25 | $-436.0K | $13.8M | ||
| Q2 25 | $-1.8M | $-29.7M | ||
| Q1 25 | $4.5M | $-4.9M | ||
| Q4 24 | $728.0K | $20.3M | ||
| Q3 24 | $1.3M | $-7.4M | ||
| Q2 24 | $-109.0K | $25.8M | ||
| Q1 24 | $-2.5M | $-3.1M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | -105.1% | ||
| Q3 25 | -3.8% | 50.4% | ||
| Q2 25 | -16.2% | -101.3% | ||
| Q1 25 | 26.4% | -18.3% | ||
| Q4 24 | 5.4% | 55.8% | ||
| Q3 24 | 9.5% | -19.6% | ||
| Q2 24 | -1.9% | 63.3% | ||
| Q1 24 | -21.4% | -8.7% |
| Q4 25 | 1.8% | -101.7% | ||
| Q3 25 | -3.1% | 54.4% | ||
| Q2 25 | -14.9% | -98.5% | ||
| Q1 25 | 26.4% | -15.5% | ||
| Q4 24 | 5.4% | 57.7% | ||
| Q3 24 | 9.3% | -20.0% | ||
| Q2 24 | -0.8% | 63.9% | ||
| Q1 24 | -21.1% | -7.9% |
| Q4 25 | $0.02 | $-0.49 | ||
| Q3 25 | $-0.03 | $0.12 | ||
| Q2 25 | $-0.12 | $-0.53 | ||
| Q1 25 | $0.31 | $-0.15 | ||
| Q4 24 | $0.05 | $0.22 | ||
| Q3 24 | $0.09 | $-0.19 | ||
| Q2 24 | $-0.01 | $0.29 | ||
| Q1 24 | $-0.19 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $84.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $1.2B |
| Total Assets | $30.2M | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $84.6M | ||
| Q3 25 | $10.3M | $204.1M | ||
| Q2 25 | $9.8M | $107.7M | ||
| Q1 25 | $3.2M | $106.4M | ||
| Q4 24 | $2.8M | $104.9M | ||
| Q3 24 | $2.9M | $108.8M | ||
| Q2 24 | $2.6M | $107.2M | ||
| Q1 24 | $4.5M | $106.5M |
| Q4 25 | $4.2M | $1.2B | ||
| Q3 25 | $3.5M | $1.2B | ||
| Q2 25 | $3.8M | $1.2B | ||
| Q1 25 | $5.5M | $1.3B | ||
| Q4 24 | $681.0K | $1.3B | ||
| Q3 24 | $-332.0K | $1.4B | ||
| Q2 24 | $-1.9M | $1.4B | ||
| Q1 24 | $-2.1M | $1.4B |
| Q4 25 | $30.2M | $6.5B | ||
| Q3 25 | $30.5M | $6.5B | ||
| Q2 25 | $32.3M | $6.8B | ||
| Q1 25 | $30.6M | $6.6B | ||
| Q4 24 | $25.2M | $6.4B | ||
| Q3 24 | $24.9M | $6.8B | ||
| Q2 24 | $26.1M | $7.1B | ||
| Q1 24 | $26.8M | $7.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $72.3M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $72.3M | ||
| Q3 25 | $600.0K | $18.5M | ||
| Q2 25 | $6.9M | $21.1M | ||
| Q1 25 | $490.0K | $15.9M | ||
| Q4 24 | $-283.0K | $132.6M | ||
| Q3 24 | $311.0K | $49.1M | ||
| Q2 24 | $-1.8M | $30.6M | ||
| Q1 24 | $-919.0K | $34.5M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | 6.54× | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
KREF
Segment breakdown not available.
